A passionate team and partners
How to Navigate the Website:
Moving Forward at the 26th Congress of the Polish Huntington Association
– May 17th, 2022
In April 2022, the Moving Forward team was invited by Danuta Lis, the President of the Polish Huntington Association, to present the project to the Polish HD community at the 26th Congress of the Polish Huntington Association/ Polskie Stowarzyszenie Choroby Huntingtona.
Participate in our Forum!
– May 6th, 2022
- This is your moment to speak and be heard.
- This is your moment to learn from others and benefit from their experience.
- This is the moment to use your voice!
Another Vibrant Possibility for Huntington’s Disease Treatment
– March 17th, 2022
Novartis Pharmaceuticals is recruiting participants for their phase IIb clinical trial called VIBRANT-HD. This study will investigate the huntingtin lowering drug Branaplam, which was originally developed for Spinal Muscular Atrophy, a devastating paediatric genetic disease.
Novartis will test Branaplam in patients with early manifest HD to check the safety of the drug in HD and learn what is the right dose to lower huntingtin, the harmful protein.